Developing an mRNA therapy for Duchenne muscular dystrophy
Developing an mRNA therapy for Duchenne muscular dystrophy Read More »
Elixirgen Therapeutics Announces Promising Phase 1/2 Data on EXG-5003, a Controllable Self-Replicating RNA (c-srRNA) Vaccine Against SARS-CoV-2
No safety concerns were observed with EXG‑5003 administration The data suggest a priming effect by EXG-5003 on the long-term cellular immunity of approved SARS-CoV-2 mRNA vaccines. The Company is exploring the use of the c-srRNA platform for the development of vaccines, cell therapies and immunotherapies for several indications BALTIMORE, October 16, 2023 – Elixirgen Therapeutics,